TICKERNERD
Menu
GLUEGLUEHealthcare · Biotechnology

GLUE Stock Forecast: Monte Rosa Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$14
−3.74% on the day

The 8 Wall Street analysts covering Monte Rosa Therapeutics, Inc. hold a median 12-month price target of $27 — +96.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$1.2B
Ticker Nerd rank
59 / 100
Median analyst target
$27
Analysts covering
8
Total return, dividends reinvested
1W
−10.5%
1M
−39.6%
YTD
−12.2%
1Y
+185.6%
From 52W high
−45.6%
From 52W low
+199.9%
$5
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GLUE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Monte Rosa Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
59 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
81
Quality
77
Momentum
76
Value
62
Revisions
58
Size
43
Issuance
41
Volatility
27
Growth
17

Accruals (81): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (17): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GLUE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GLUE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26GLUEHigh $37Median $27Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $25Median $27High $37

The green dot is the last close — the median target sits +96.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
7 Aug 2026GuggenheimMaintainsBuy$35 → $28
7 Aug 2026JP MorganMaintainsOverweight$31 → $27
7 Aug 2026Wells FargoMaintainsOverweight$29 → $27
3 Aug 2026WedbushMaintainsOutperform$37 → $27
30 June 2026GuggenheimMaintainsBuy$30 → $35
30 June 2026GuggenheimMaintainsBuy—
11 May 2026JP MorganMaintainsOverweight—
18 Mar 2026GuggenheimMaintainsBuy—
18 Mar 2026Wells FargoMaintainsOverweight—
14 Jan 2026Piper SandlerReiteratesOverweight—
8 Jan 2026GuggenheimMaintainsBuy—
8 Jan 2026Wells FargoMaintainsOverweight—
16 Dec 2025Wells FargoUpgradeOverweight—
7 Nov 2025Wells FargoMaintainsEqual-Weight—
21 Mar 2025WedbushMaintainsOutperform—
21 Mar 2025Wells FargoMaintainsEqual-Weight—
12 Mar 2025LifeSci CapitalInitiatesOutperform—
19 Dec 2024Wells FargoDowngradeEqual-Weight—
12 Sept 2024WedbushReiteratesOutperform—
12 Aug 2024Wells FargoMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GLUE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

GLUE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
1
Fundamentals

Monte Rosa Therapeutics, Inc. (GLUE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
49.2×

Cheaper than 15% of US stocks

Price / sales
42.5×

Cheaper than 6% of US stocks

Price / book
2.5×

Cheaper than 40% of US stocks

EV / EBITDA
−3.7×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
−61.3%

Higher than 4% of US stocks

Earnings growth (YoY)
−61.3%

Higher than 8% of US stocks

Gross margin
—
Operating margin
−547.8%

Higher than 7% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−42.7%

Higher than 23% of US stocks

Return on assets
−21.6%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

GLUE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GLUEMonte Rosa Therapeutics, Inc.$1.2B
59
CRVSCorvus Pharmaceuticals, Inc.$1.2B
54
IMTXImmatics NV$1.2B
39
OBXObsidian Therapeutics, Inc.$1.2B
62
ODTXOdyssey Therapeutics, Inc.$1.2B
1
SANASana Biotechnology, Inc.$1.2B
30
APMDApnimed, Inc.$1.2B
0

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Monte Rosa Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GLUE news & analysis

Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

GlobeNewsWire · 24 Aug 2026positive

Monte Rosa Therapeutics announced that the first patient has been dosed in MODeFIRe-1, a Phase 2 study evaluating MRT-2359 in combination with apalutamide in patients with AR mutation-positive metastatic castration-resistant prostate cancer.

Why it matters — This marks the initiation of patient dosing for a Phase 2 clinical program combining MRT-2359 with apalutamide, advancing Monte Rosa's pipeline in metastatic castration-resistant prostate cancer.

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 6 Aug 2026negative

Monte Rosa Therapeutics reported a second-quarter loss of $0.43 per share, wider than the Zacks Consensus Estimate of a $0.25 loss and compared with a $0.15 loss per share a year ago. The company also missed revenue estimates.

Why it matters — A GLUE watcher would care because the company's quarterly loss widened more than analyst expectations and revenue came in below estimates.

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

GlobeNewsWire · 6 Aug 2026positive

Monte Rosa Therapeutics reported its second quarter 2026 financial results and business updates, including completed enrollment for the GFORCE-1 study of MRT-8102 in subjects with elevated CVD risk (readout expected in H2 2026) and plans to initiate multiple MRT-8102 Phase 2 studies. The company also activated the MODeFIRe-1 Phase 2 study of MRT-2359 in mCRPC patients with AR mutations and a Phase 2a/b trial for MRT-6160 in Sjögren's disease to be conducted by Novartis, with cash of $626.0 million expected to support operations into 2029.

Why it matters — GLUE watchers would care because the company is executing across its clinical-stage portfolio with multiple Phase 2 trial activations and upcoming readouts, supported by a balance sheet expected to fund operations into 2029.

FAQ

Frequently asked questions about GLUE stock

What is the GLUE stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Monte Rosa Therapeutics, Inc. have a median 12-month price target of $27, with estimates ranging from $25 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GLUE stock a buy right now?

Of the 8 analysts covering Monte Rosa Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Monte Rosa Therapeutics, Inc. 59 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GLUE?

As at 22 Aug 2026, Monte Rosa Therapeutics, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (81 of 100).

Will GLUE stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +96.1% from the last close, and Ticker Nerd's factor model ranks Monte Rosa Therapeutics, Inc. 59 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GLUE stock forecast for 2030?

No analyst covering Monte Rosa Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GLUE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $37 over the next 12 months.

How has GLUE stock performed over the past year?

Monte Rosa Therapeutics, Inc. returned +185.6% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Monte Rosa Therapeutics, Inc. do?

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing molecular glue degraders (MGDs), a class of small molecule drugs that harness the body's natural protein destruction mechanisms to selectively eliminate therapeutically relevant proteins.

What is the latest news on GLUE?

The most recent item we track (GlobeNewsWire, 24 Aug 2026): "Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer". Monte Rosa Therapeutics announced that the first patient has been dosed in MODeFIRe-1, a Phase 2 study evaluating MRT-2359 in combination with apalutamide in patients with AR mutation-positive metastatic castration-resistant prostate cancer.

Company

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing molecular glue degraders (MGDs), a class of small molecule drugs that harness the body's natural protein destruction mechanisms to selectively eliminate therapeutically relevant proteins. The company employs its proprietary Quantitative and Engineered Elimination of Neosubstrates (QuEEN) platform, which integrates artificial intelligence and experimental tools to enable target-centric discovery and rational design of MGD product candidates. Key pipeline assets include MRT-2359, an orally bioavailable MGD targeting the GSPT1 protein for potential treatment of MYC-driven tumors such as metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Additional candidates like MRT-6160 and MRT-8102 address needs in oncology and autoimmune diseases. Monte Rosa Therapeutics, Inc. operates within the biotechnology and medical research sector, advancing novel therapeutic modalities to tackle serious diseases through precision protein degradation.

CEO Dr. Markus Warmuth M.D. · 173 employees · United States · https://www.monterosatx.com